Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 12, 2020 08:00 ET | Source: Aravive, Inc.

Aravive To Present at The 2020 RBC Capital Markets Global Healthcare Conference

HOUSTON, May 12, 2020 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage biopharmaceutical company developing treatments designed to halt the progression of life-threatening...
May 06, 2020 16:05 ET | Source: Aravive, Inc.

Aravive Reports First Quarter 2020 Financial Results and Provides Recent Corporate Updates

HOUSTON, May 06, 2020 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage biopharmaceutical company developing treatments designed to halt the progression of life-threatening...
April 30, 2020 08:00 ET | Source: Aravive, Inc.

Aravive and WuXi Biologics Form Strategic Collaboration to Develop Novel High-Affinity Bispecific Antibodies Targeting Cancer and Fibrosis Using the WuXiBody™ Platform

HOUSTON and SHANGHAI, April 30, 2020 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage biopharmaceutical company, and WuXi Biologics ("WuXi Bio") (2269.HK), a global company with...
April 09, 2020 07:08 ET | Source: Aravive, Inc.

Aravive Announces Board Composition and Executive Management Transitions

Healthcare Entrepreneur Fred Eshelman, Pharm.D., Appointed Board Chairman Aravive’s Chief Scientific Officer, Gail McIntyre, Ph.D., Appointed CEO Aravive to Host Conference Call Today at 9:00 AM ET ...
March 30, 2020 08:00 ET | Source: Aravive, Inc.

Aravive Announces AVB-500 Improves Anti-Tumor Effects when Combined with Anti-Angiogenic Bevacizumab or PARP Inhibitor Olaparib in Preclinical Models of Uterine Cancer

Inhibition of GAS6/AXL signaling induces ‘BRCAness’ in preclinical model of ovarian cancer, increasing response to platinum chemotherapy and PARP inhibitor Multiple Abstracts Published on Website of...
March 27, 2020 08:00 ET | Source: Aravive, Inc.

Aravive Reports Fourth Quarter and Twelve Months Ended December 31, 2019 Financial Results and Provides Recent Corporate Updates

AVB-500 Phase 1b dose escalation ongoing at 20 mg/kg dose in platinum resistant ovarian cancer with potential for topline data in summer 2020Company announces clinical trial updates for clear cell...
March 24, 2020 08:00 ET | Source: Aravive, Inc.

Aravive Announces Initiation of Investigator-Sponsored Phase 1/2 Study of AVB-500 in Combination with Avelumab in Patients with Advanced Urothelial Carcinoma (COAXIN)

HOUSTON, March 24, 2020 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage biopharmaceutical company, announced that the first patient has been dosed in an investigator-sponsored...
February 25, 2020 16:07 ET | Source: Aravive, Inc.

Aravive To Present at The Cowen and Company 40th Annual Health Care Conference

HOUSTON, Feb. 25, 2020 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage biopharmaceutical company, today announced that it will present at Cowen and Company's 40th Annual Health...
February 18, 2020 08:00 ET | Source: Aravive, Inc.

Aravive Announces Dose Escalation of AVB-500 in Recurrent Platinum Resistant Ovarian Cancer Phase 1b Trial

Dose escalation of AVB-500 to 20mg/kg dose follows positive recommendation by independent Data Monitoring Committee review Plan to initiate Phase 2/3 study in Platinum Resistant Ovarian Cancer by...
January 13, 2020 08:00 ET | Source: Aravive, Inc.

Aravive Receives IND Clearance for Phase 1b/Phase 2 Clinical Trial of AVB-500 in Patients with Clear Cell Renal Cell Carcinoma

HOUSTON, Jan. 13, 2020 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has cleared the...

Next Page keyboard_arrow_right